Generic oncology sterile injectables are used for the treatment of various types of cancers such as ovarian, breast, and lung. Generic oncology sterile injectables products are relatively cheaper than branded counterparts. Treatment cost is a major concern for cancer patients, especially in emerging economies such as India, Brazil, and China. Therefore, governments of such countries are taking efforts to reduce cost of medications and increase its accessibility. For instance, the National Pharmaceutical Pricing Authority (NPPA) of India reduced the prices of few cancer products by 86% in March 2017.
Generic oncology sterile injectables have a huge potential in such countries, where patient population is high; however, spending power is relatively low. Furthermore, patent expiry of product is expected to fuel growth of the generic oncology sterile injectables market during the forecast period. The emergence of biosimilars have also impacted the growth of generics oncology sterile products. For instance, according to the Journal of Generics and Biosimilars Initiative, 2017, biosimilars have a major share in Europe and in the U.S. since 2013 and 2015, respectively, and the share of biosimilars is expected to increase significantly in the biologicals market. This is expected to eventually boost growth of the generic oncology sterile injectable market.
Market Dynamics
Generic oncology sterile injectables market is gaining significant traction due to rising prevalence of cancer cases. For instance, according to the World Health Organization, in 2018, around 18.1 million new cases of cancer and 9.6 million deaths were reported, globally.
However, lack of awareness amongst the people in low-income and middle-income countries regarding cervical cancer is expected to hinder growth of the generic oncology sterile injectables market during the forecast period. Cervical cancer is one of the most common cancers among women of reproductive age in low-income and middle-income countries. For instance, according to The International Agency for Research on Cancer’s (IARC) report of 2013, cervical cancer is mostly prevalent in low-income countries of sub-Saharan Africa.
Key features of the study:
- This report provides in-depth analysis of the global generic oncology sterile injectable market, market size (US$ Mn), and compound annual growth rate (CAGR (%) for the forecast period, 2019-2027, considering 2018 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global generic oncology sterile injectable market based on the following parameters: company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
- Key players covered as a part of this study include Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global generic oncology sterile injectable market report caters to various stakeholders in this industry, which include investors, product manufacturers, distributors, and suppliers of generic oncology sterile injectable market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
- Global Generic Oncology Sterile Injectable Market, by Product Type:
- Chemotherapy
- Alkylating agents
- Antimetabolites
- Plant Alkaloids
- Antitumor Antibiotics
- Others
- Monoclonal Antibodies
- Cytokines
- Peptide Hormones
- Global Generic Oncology Sterile Injectable Market, by Disease Indication:
- Ovarian Cancer
- Breast Cancer
- Lung Cancer
- Pancreatic Cancer
- Others
- Global Generic Oncology Sterile Injectable Market, by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Generic Oncology Sterile Injectable Market, by Region:
- North America
- By Country:
- By Product Type:
- Chemotherapy
- Alkylating agents
- Antimetabolites
- Plant Alkaloids
- Antitumor Antibiotics
- Others
- Monoclonal Antibodies
- Cytokines
- Peptide Hormones
- By Disease Indication:
- Ovarian Cancer
- Breast Cancer
- Lung Cancer
- Pancreatic Cancer
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Product Type:
- Chemotherapy
- Alkylating agents
- Antimetabolites
- Plant Alkaloids
- Antitumor Antibiotics
- Others
- Monoclonal Antibodies
- Cytokines
- Peptide Hormones
- By Disease Indication:
- Ovarian Cancer
- Breast Cancer
- Lung Cancer
- Pancreatic Cancer
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Product Type:
- Chemotherapy
- Alkylating agents
- Antimetabolites
- Plant Alkaloids
- Antitumor Antibiotics
- Others
- Monoclonal Antibodies
- Cytokines
- Peptide Hormones
- By Disease Indication:
- Ovarian Cancer
- Breast Cancer
- Lung Cancer
- Pancreatic Cancer
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Product Type:
- Chemotherapy
- Alkylating agents
- Antimetabolites
- Plant Alkaloids
- Antitumor Antibiotics
- Others
- Monoclonal Antibodies
- Cytokines
- Peptide Hormones
- By Disease Indication:
- Ovarian Cancer
- Breast Cancer
- Lung Cancer
- Pancreatic Cancer
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Product Type:
- Chemotherapy
- Alkylating agents
- Antimetabolites
- Plant Alkaloids
- Antitumor Antibiotics
- Others
- Monoclonal Antibodies
- Cytokines
- Peptide Hormones
- By Disease Indication:
- Ovarian Cancer
- Breast Cancer
- Lung Cancer
- Pancreatic Cancer
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Product Type:
- Chemotherapy
- Alkylating agents
- Antimetabolites
- Plant Alkaloids
- Antitumor Antibiotics
- Others
- Monoclonal Antibodies
- Cytokines
- Peptide Hormones
- By Disease Indication:
- Ovarian Cancer
- Breast Cancer
- Lung Cancer
- Pancreatic Cancer
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
- Eli Lilly & Company*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Biocon Ltd.
- Baxter International Inc.
- Hikma Pharmaceuticals PLC
- Mylan N.V.
- Sandoz International GmbH
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
“*” marked represents similar segmentation in other categories in the respective section.
